A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY)
- Registry ID
- ALN-TTRSC04-003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ALNYLAM PHARMACEUTICALS INC
- Start date
- 2025-11-19
- Last update
- 2025-06-20
Conditions
- CARDIOMYOPATHY
- TRANSTHYRETIN MEDIATED AMYLOIDOSIS
Related clinical trials
- TRITON-PN: A PHASE 3, GLOBAL, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (HATTR-PN)
- PHASE 2,ADAPTIVE,DOUBLE-BLINDED,PLACEBO-CONTROLLED,RANDOMIZED,MULTI-CENTER TRIAL TO EVALUATE THE EFFICACY,SAFETY AND TOLERABILITY OF INTRACORONARY INFUSION OF AB-1002 IN ADULT SUBJECTS WITH NYHA CLASS III HEART FAILURE AND NON-ISCHEMIC CARDIOMYOPATHY
- A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF
ACORAMIDIS FOR TRANSTHYRETIN AMYLOIDOSIS PREVENTION IN THE YOUNG (ACT-EARLY TRIAL)
- OPEN-LABEL EXTENSION STUDY OF LONG-TERM SAFETY AND EFFICACY OF NNC6019-0001 IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
- TARGETED THERAPY WITH GLYCOGEN SYNTHASE KINASE-3 INHIBITION FOR ARRHYTHMOGENIC CARDIOMYOPATHY (TARGET)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID POLYNEUROPATHY
View on source registry